ABSTRACT

Conclusion:

The treatment of UDCA in ICP positively effects on level of pruritus, but does not contribute to regression of ALT level.

Results:

The mean age of pregnant was 29.9±6.5 and the mean week of pregnancy was 31.8±3,74. There was no significant difference in terms of ALT level between before and after period of UDCA treatment (106.13 ± 91.27 vs. 45.8 ± 35.76 U / L, p = 0.87, respectively). A significant difference was observed in terms of ALT level between postpartum period and post-UDCA treatment (22.2 ± 5.79 vs. 45.8 ± 35.76 U / L, p = 0.002, respectively). There was a significant difference in terms of visual analog scores between before and after period of UDCA treatment (6.6 ± 1.44 vs. 2.03 ± 1.49, p = 0.02, respectively).

Methods:

A total of 30 pregnant diagnosed with ICP in the Gastroenterology outpatient clinic of Kanuni Sultan Süleyman Training and Research Hospital were enrolled in the study in 2018. Data including patient age, pregnancy week, delivery week, pruritus score, level of SBA and ALT levels were recorded.

Objective:

Intrahepatic Cholestasis of Pregnancy (ICP) is a pregnancy complication characterized by pruritus, elevation in liver enzymes and concentration of serum bile acids (SBA). In the current study, we aimed to investigate the relationship after treatment of ursodeoxycholic acid (UDCA) in patients with ICP between pruritus and the level of alanine aminotransferase (ALT) and SBA.